DANCAN Stock Overview
A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.0056 |
| 52 Week High | DKK 0.13 |
| 52 Week Low | DKK 0.0026 |
| Beta | 2.08 |
| 11 Month Change | 21.74% |
| 3 Month Change | -17.65% |
| 1 Year Change | -86.34% |
| 33 Year Change | -99.84% |
| 5 Year Change | n/a |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| DANCAN | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 86.7% | -5.5% | -2.4% |
| 1Y | -86.3% | 9.1% | 10.9% |
Return vs Industry: DANCAN underperformed the Swedish Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: DANCAN underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| DANCAN volatility | |
|---|---|
| DANCAN Average Weekly Movement | 20.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DANCAN's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DANCAN's weekly volatility has decreased from 30% to 20% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Jeppe Rasmussen | www.dancann.com |
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros.
DanCann Pharma A/S Fundamentals Summary
| DANCAN fundamental statistics | |
|---|---|
| Market cap | DKK 7.71m |
| Earnings (TTM) | -DKK 59.11m |
| Revenue (TTM) | DKK 8.22m |
1.0x
P/S Ratio-0.1x
P/E RatioIs DANCAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DANCAN income statement (TTM) | |
|---|---|
| Revenue | DKK 8.22m |
| Cost of Revenue | DKK 9.64m |
| Gross Profit | -DKK 1.42m |
| Other Expenses | DKK 57.69m |
| Earnings | -DKK 59.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | -0.038 |
| Gross Margin | -17.27% |
| Net Profit Margin | -719.11% |
| Debt/Equity Ratio | 0% |
How did DANCAN perform over the long term?
See historical performance and comparison